Assessing Spyre Therapeutics (SYRE) valuation after expanded SPY003 license with Paragon. June 03, 2026 Spyre Therapeutics (SYRE) stock is back in focus after the company amended its SPY003 license with Paragon Therapeutics, expanding rights beyond inflammatory bowel disease to broader uses while keeping clear dosing limits for non IBD indications. The expanded SPY003 license and recent conference appearance come after a sharp run, with the stock's 90 day share price return of 68.68% and a very large 1 year total shareholder return. However, the 7 day share price return is down 6.10% as some investors reassess risk around execution on the broader pipeline rights. If this kind of biotech re rating has your attention, it could be a good moment to look beyond a single stock and review 39 healthcare AI stocks With Spyre's shares up 68.68% over 90 days and the stock trading at a discount to the US$95.20 consensus target, investors now have to ask: is there still a reasonable entry point here, or is future growth already priced in? Price-to-Book of 11.7x: is it justified? Spyre Therapeutics trades on a P/B of 11.7x, which sits close to a peer average of 12.2x but far above the wider US biotech group. P/B compares the market value of the equity to the accounting value of net assets. This often matters for early stage biotechs that have little or no revenue and where earnings-based metrics are less useful. At a last close of $69.16, investors are tying a relatively high equity value to a business that reports no meaningful revenue and a net loss of $148.703m. The key question is what that premium is really reflecting. Spyre is currently unprofitable, is forecast to remain unprofitable over the next 3 years, and earnings are expected to decline by an average of 17% per year over that period. On top of that, shareholders have been substantially diluted in the past year and the company reports a negative return on equity of 26.75% with all liabilities coming from higher risk sources of funding rather than customer deposits. Compared with the broader US Biotechs industry average P/B of 2.6x, Spyre's 11.7x multiple is far richer, which signals that the market is pricing in a very optimistic view on the pipeline relative to current fundamentals. However, against its closer peer set, the same 11.7x sits only slightly below the 12.2x average. This suggests the stock is roughly in line with companies that investors consider similar on key characteristics. Result: Price-to-book of 11.7x (ABOUT RIGHT) However, there are still clear pressure points, including ongoing losses of $148.703m and reliance on higher risk funding sources that could quickly challenge today's premium valuation. Next steps. With sentiment pulled between clear risks and meaningful upside potential, it makes sense to move quickly and test the numbers yourself rather than rely on headlines. To see both sides set out clearly, start with the 1 key reward and 4 important warning signs Looking for more investment ideas? If you are serious about building a stronger portfolio, do not stop at a single biotech stock. Use targeted screens to quickly surface other opportunities that fit your style. * Spot potential turnaround candidates with room to run by scanning 24 elite penny stocks with strong financials. * Hunt for quality at a reasonable price by checking out 46 high quality undervalued stocks. * Balance return potential with resilience by reviewing the 63 resilient stocks with low risk scores. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. New: manage all your stock Portfolios in one place. - Connect an unlimited number of Portfolios and see your total in one currency - Be alerted to new Warning Signs or Risks via email or mobile - Track the Fair Value of your stocks Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Spyre Therapeutics amended its SPY003 license agreement with Paragon Therapeutics, expanding rights beyond inflammatory bowel disease to all therapeutic, prophylactic, palliative and diagnostic uses. However, dosing restrictions remain in place until at least 2028 for combinations and 2030 for monotherapy outside inflammatory bowel disease. The amendment broadens Spyre's development options for SPY003, though near-term catalysts still focus on Phase 2 readouts from SKYLINE and SKYWAY trials and deployment of its recent $403 million funding raise. The license change primarily affects future partnering and change-of-control scenarios. The pre-revenue company faces key risks including clinical data setbacks, ongoing dilution and execution challenges. Fair value estimates from the Simply Wall St Community vary widely, reflecting uncertainty around the broadened license terms against ongoing clinical and funding risks.